Cerdelga (eliglustat) Helps Gaucher Type 3 Patient
FEBRUARY 15, 2017
Alexander Bloomfield, MBBS
At WORLDSymposium in San Diego, CA, Alexander Bloomfield, MBBS, MSc of the Royal Manchester Children's Hospital discusses a case report in which a patient with Gaucher disease type 3 benefited from the treatment of eliglustat, a drug currently approved for Gaucher disease type 1.
Bloomfield A, Mercer J, Church HJ, et al. Combined therapeutic approach to protein losing enteropathy complicating type 3 Gaucher disease using eliglustat. Presented at WORLDSymposium; San Diego, CA; February 13-16, 2017.